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The global COVID-19 (SARS-CoV2, COVID-19) tsunami
caused by SARSCoV2 is inundating and often-overwhelm-
ing health care systems in most countries and regions.
Numbers of infected people and the death toll are increas-
ing, with the fortunate exception of the first hit or the best
prepared regions of East Asia. While some governments
have had success in containing the spread of the virus,
the global situation is constantly changing, usually for the
worse, and the measures applied by different countries
have often been ineffective.
Are we responding too slowly or are our measures too
mild or too generic to contain the virus? It is clear that we
are missing something, as most of our attempts have been
unable to stop the spread of infection. SARS-CoV2 is a new
virus and we are missing much key information that is vital
to develop and implement fast and appropriate
interventions.
Data-driven action is needed to improve the effectiveness
and efficiency of interventions at all phases of this pandemic.
The present commentary addresses a few of the key—(and
we sincerely hope), obvious issues to blunt the trajectory of
COVID-19—not just in this early phase of the pandemic, but
also during the subsequent more pervasive and quiescent
phases of spread and viral mutation.
At present, we do not doubt that isolation and social
distancing are the most effective measures to contain the
virus, but it is critical that we define at the finest granularity
what virus variants are infecting what populations. What
genetic, developmental, and environmental cofactors mod-
ulate the severity of COVID-19 diseases? Can we gain
enough information in the next three months to triage
and ultimately to vaccinate the most critical subgroups
within each population?
Isolation will be far more effective if we know who we
need to isolate, who is infected with which SARS-CoV2
variant (and there are already many), and the precise
locales of infections. We need to identify both those who
have been exposed and those who are infected to be
efficient to mitigate and possibly eliminate the COVID-19
pandemic.
Authors of this article propose the following seven
points for immediate action:
1. The first goal should be identification of all or almost
all those infected and to achieve effective isolation
against a backdrop of tremendous variation in
social setting and housing space. Regardless of
social context, to achieve this goal will require a
great deal more testing than has been typical even
in wealthy and nominally well-prepared European
and North American countries. In areas outside of
hot spots, we need to test samples using a variety
of selection parameters: (1) those entering from
areas of high risk, (2) individuals working in health
care, (3) individuals with high mobility within a com-
munity, (4) a systematic random sample by age, sex,
ancestry, and social setting. There is hard evidence
that COVID-19 infection is contagious 2–3 days
before any symptoms and that a large proportion of
infected people are symptomless.1–3 This finding
explains why the simple isolation based on clinical
symptoms does not work for the present pandemic.
In addition, there is also evidence that the regions
with significant testing activity (South-Korea,
https://news.sky.com/story/coronavirus-experi
ment-in-northern-italian-town-halts-all-new-infec
tions-after-trial-11959587) have been successful in
isolating the infection and stopping the spread.
2. Why is it important to identify those infected and
isolate them? The best way to think of this infection
right now is to consider the domino model. One
single infected individual, with a transmission rate
of 2 (one person infecting two people, it is R0¼ 2)
will give a total infected population of over a million
people in just two weeks. However, if half of these
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dominos were to be taken out (isolated) every three
days, leaving the remainder to continue infecting at
the same rate, the total number of infections after two
weeks will be less than 5000. In case of the COVID-
19, the R0 value could be as high as 4.5 and this
means much wider spread, causing the difficulties
to contain it.4 There is no substitute for social isola-
tion of infected persons, but we have to know who
these subjects are that we need to isolate. If testing of
very large sections of the whole population on a reg-
ular basis is not feasible for logistic or economic rea-
sons, social isolation of very large sections of the
population is the only effective means of contain-
ment. Ideally, in a scenario that protects the most
vulnerable sections in the population, slow progres-
sion of the infection amongst the least vulnerable
sections of the population could contribute to the
development of herd immunity. Once an effective
vaccine has become available, of course mass vacci-
nation will achieve population-based immunity. The
success of this approach will depend on our efficien-
cy to detect the infected persons by repeated and
mass-based testing, until an efficient assay for the
identification of persons resistant to infection or re-
infection becomes available.
3. We need a global mobilization to support much
higher and faster testing that is necessary to fulfill
the goal of identifying the journey of the virus in
the population and targeting the most at risk areas
in the community. We need to engage researchers
and available resources across the globe. This
includes diagnostic laboratories, hospital systems,
universities, research institutes, and potentially any
group who can perform validated reverse
transcription polymerase chain reaction (RT-PCR) or
polymerase chain reaction (PCR) tests in areas farther
removed from diagnostic and health care facilities.
The governments need to provide resources to run
the tests and to organize the custody of collected
samples. After identifying the infected persons, we
need to trace back their whereabouts and isolate the
infected persons. This is the only way to stop the
COVID-19 pandemic in the foreseeable future.
4. Systematic retesting of individuals, especially in the
vicinity of hot spots, should be performed within a
week or 10 days to identify the fraction of cases who
had virus, but with undetectable levels upon initial
testing. We also need to start testing for seroconver-
sion to detect those who developed immunity. These
could be infected people, symptomatic or otherwise,
who developed neutralizing antibodies, thus devel-
oping possible resistance to re-infection.
5. Intensive testing and identification of virus carriers
help us to minimize risk to those working on the
health care frontlines. These are health care profes-
sionals, law and immigration officers, those in the
energy, transportation, and utility service sectors,
social workers, food and other service providers,
and any group with high mobility between areas.
Even in lockdown, our societies have to maintain
essential functions and we have to protect those
who are key to these core functions.
6. We need an intensive global collaborative research
effort to describe the clinical course and virus cycle
based on highly diverse patient populations. Why do
some individuals not develop symptoms, why are
children relatively inured to clinical disease? How
do genetic variants in genes such as ACE2 modulate
the infection cascade, influence the susceptibility to
SARS-CoV2? What is the duration and efficacy of
immunity after initial infection? What is the compar-
ative virulence of different variants of SARS-CoV2
and how do these variants interact with genetic and
environmental factors of host humans?
7. Research results related to COVID-19 should be sub-
mitted, reviewed, published quickly, and made freely
available. We need to maximize the amount of infor-
mation we have, which is the best way to outrun and
overcome COVID-19 and subsequent pandemics.
We encourage the governments and research communi-
ties to initiate immediate global molecular testing for the
SARS-CoV2 infection, as using only the clinical symptoms
to detect infected persons is too slow (R0¼ 4.5).4 We call for
the initiation of precision epidemiology that is a
modernized workflow taking into account the viral
genome, the host genome and response, exposure history,
and the disease trajectory. Precision epidemiology will help
us to overcome the ongoing pandemic and would protect
our communities from potential outbreaks in the future.
Extensive testing combined with appropriate data
interpretation is a fundamental requirement to stop the
ongoing pandemic. The testing needs to be repeated
several times as persons with negative tests could become
positive the next day as a result of a new infection or the
replication of the virus. In either case, the individual testing
negative could still transmit the infection and the false
assurance of negative results could have severely
negative impacts. Repeated testing will reduce the risk of
missing these events. These would be the first steps to stop
the propagation of the virus. Additional molecular tests for
re-infection resistance, immunological response or clinical
prognosis are required in the next phase of the fight against
COVID-19. These are some of the most important steps we
are required to take in order to overcome this pandemic
and to be better prepared for any similar outbreaks in the
future.
DECLARATION OF CONFLICTING INTERESTS
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of this
article.
678 Experimental Biology and Medicine Volume 245 April 2020
...............................................................................................................................................................
FUNDING
The author(s) received no financial support for the research,
authorship, and/or publication of this article.
ORCID iDs
Sulev Koks https://orcid.org/0000-0001-6087-6643
Nicola Conran https://orcid.org/0000-0001-5726-7919
Shaw-Jeng Tsai https://orcid.org/0000-0002-3569-5813
Gordon Awandare https://orcid.org/0000-0002-8793-3641
Steven R Goodman https://orcid.org/0000-0002-7607-6525
REFERENCES
1. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel
coronavirus (COVID-19) infections. Int J Infect Dis 2020;93:284–286
2. Tindale L, Coombe M, Stockdale JE, Garlock E, Lau WYV, Saraswat M,
Lee Y-H, Zhang L, Chen D, Wallinga J, Colijn C. Transmission interval
estimates suggest pre-symptomatic spread of COVID-19. medRxiv 2020.
doi: https://doi.org/10.1101/2020.03.03.20029983
3. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. Substantial
undocumented infection facilitates the rapid dissemination of novel
coronavirus (SARS-CoV2). Science (New York, NY) 2020 Mar 16. pii:
eabb3221. doi: 10.1126/science.abb3221.
4. Liu T, Hu J, Xiao J, He G, Kang M, Rong Z, Lin L, Zhong H, Huang Q,
Deng A, Zeng W, Tan X, Zeng S, Zhu Z, Li J, Gong D, Wan D, Chen S,
Guo L, Li Y, Sun L, Liang W, Song T, He J, Ma W. Time-varying trans-
mission dynamics of novel coronavirus pneumonia in China. bioRxiv
2020. doi: https://doi.org/10.1101/2020.01.25.919787
Koks et al. Tackling COVID-19 679
...............................................................................................................................................................
